Lung cancer diagnosis is moving beyond identifying a suspicious shadow on a scan. Clinicians increasingly need to establish whether a nodule is malignant, determine its molecular characteristics and identify the tests that can guide treatment. This changing clinical requirement is bringing imaging technology, laboratory chemistry, genomic analysis and precision oncology closer together.
The World Health Organization reported an estimated 2.5 million new lung cancer cases and 1.8 million deaths worldwide in 2022, highlighting the importance of effective detection and timely diagnosis. WHO
-
For instance, in August 2026, Fortis Hospitals Bengaluru has established a special Lung Nodule Clinic to aid in the multidisciplinary care model's early detection and thorough treatment of lung cancer. The clinic assessed 38 individuals with lung nodules during the course of its six-month pilot program. Nine of these had non-cancerous nodules, ten had infectious lesions, and 19 had lung cancer, underscoring the importance of thoroughly assessing any suspicious lung lesions.
The CT scan is becoming a Starting Point, Not the Final Answer
-
Low-dose computed tomography (LDCT) remains an important tool for screening eligible people at high risk of lung cancer.
-
It can reveal small pulmonary nodules before symptoms become apparent, but a suspicious finding does not automatically establish cancer. Further imaging, tissue sampling and pathological assessment may be necessary.
-
In the United States, screening recommendations cover adults aged 50–80 with a qualifying smoking history. The challenge is to connect screening with reliable follow-up, particularly when scans reveal nodules that require monitoring or additional investigation. National Cancer Institute
-
For diagnostic laboratories and healthcare providers, this creates demand for coordinated imaging, biopsy procedures, pathology services and molecular testing rather than reliance on a single diagnostic method.
AI Enters the Radiology Workflow with a More Practical Purpose
Artificial intelligence is increasingly being evaluated as a way to help radiologists assess CT scans, prioritize suspicious findings and manage large screening workloads.
A 2025 study using data from the UK Lung Cancer Screening trial evaluated AI as an initial reader for CT scans. The researchers reported that the system detected all 31 baseline-round lung cancers in the study dataset, with an estimated potential to reduce CT-reading workload by up to 79%. These findings demonstrate potential in a specific study setting, not a guarantee of equivalent performance in every hospital.
The practical opportunity lies in combining computational analysis with radiologists' expertise. AI may help flag suspicious nodules, but clinical interpretation and appropriate follow-up remain essential.
Liquid Biopsy Brings Molecular Clues into a Blood Sample
Tissue biopsy can provide essential information about a tumour, but obtaining sufficient material is not always straightforward. Liquid biopsy offers another route by analysing circulating cell-free DNA in blood for specific tumour-associated genetic alterations.
The US Food and Drug Administration has authorised liquid biopsy tests for defined uses in non-small cell lung cancer. For example, FoundationOne Liquid CDx can identify certain genetic alterations relevant to treatment selection. However, a negative blood-test result does not necessarily mean that the tumour lacks an actionable mutation; tissue testing may still be required when feasible. FDA device documentation
This distinction is important: liquid biopsy is a valuable complement to tissue-based diagnosis, not a universal replacement for biopsy or an established stand-alone screening test for the general population.
Why Chemical Reagents and Molecular Assays Matter More Than Ever?
-
Behind each molecular result is a laboratory process involving sample preparation, nucleic-acid extraction, amplification or sequencing, analytical controls and interpretation.
-
The quality of reagents, assay specificity and specimen integrity can influence whether a clinically meaningful alteration is detected.
-
Immunohistochemistry also plays a critical role. Tests for proteins such as PD-L1 help clinicians assess potential suitability for certain immunotherapies, while molecular assays investigate alterations in genes including EGFR, ALK, KRAS, MET and HER2.
-
For life-science suppliers, this creates a specialised intersection between diagnostic chemistry, molecular biology and oncology laboratory infrastructure.
Explore our latest updated insights here: https://www.24lifesciences.com/lung-cancer-diagnostics-market-8691
Recent FDA Decisions Show How Diagnostics and Treatments Are Converging
Regulatory developments during 2025 illustrate why companion diagnostics are becoming increasingly important in lung cancer care.
-
In July 2025, the FDA approved sunvozertinib for certain patients with advanced non-small cell lung cancer carrying EGFR exon 20 insertion mutations. The agency also approved the Oncomine Dx Express Test to identify patients with the relevant alteration.
-
In November 2025, the FDA granted accelerated approval to sevabertinib for eligible patients with HER2-mutated non-small cell lung cancer and approved the Oncomine Dx Target Test as a companion diagnostic.
These decisions demonstrate how identifying a particular mutation can determine whether a patient qualifies for a specific targeted treatment.
The Next Diagnostic Breakthrough Must Also Work in Everyday Healthcare
Advanced testing delivers value only when hospitals can obtain suitable samples, access validated laboratory methods and return results in time to inform treatment decisions. Costs, reimbursement, laboratory capacity and uneven access to specialist pathology can all affect implementation.
The central development in the lung cancer diagnostics market is therefore not simply the arrival of another testing technology. It is the integration of imaging, pathology, molecular analysis and clinical decision-making into a more coordinated diagnostic pathway.
For healthcare systems, laboratories and life-science manufacturers, the priority is to make accurate, clinically useful testing accessible while preserving appropriate validation and follow-up. Earlier detection matters, but so does ensuring that every meaningful result leads to the right next clinical step.